The company's missed forecasts and lack of positive strategi...
The company's missed forecasts and lack of positive strategic review results may dampen investor sentiment. However, cost savings from discontinuing early-stage drugs and reducing staff, along with share buybacks, could offset some negativity.
Aurinia Drops After Q4 Miss; Strategic Review Fails
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment